OCTIMET develops highly selective MET kinase inhibitors, OMO-1 and OMO-2, to target cancer cell proliferation and survival pathways. OMO-1 is an oral small molecule that has shown potent activity in preclinical cancer models, while OMO-2 is a dual inhibitor under investigation for lung cancer and potential broader oncology applications.
Funding
$11.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers rely on dysregulation of MET kinase and RAS pathways for proliferation and survival, presenting a challenge for traditional therapies. Single-target inhibitors may not be sufficient to overcome resistance mechanisms or address the complexity of these interconnected signaling networks.
Solution
OCTIMET develops highly selective MET kinase inhibitors, OMO-1 and OMO-2, designed to disrupt cancer cell proliferation and survival pathways. OMO-1 is an orally available small molecule that has demonstrated activity in preclinical cancer models. OMO-2 is a dual MET and RAS pathway inhibitor currently under preclinical investigation as a targeted therapy for lung cancer. OMO-2 may also have broader oncology applications when used in combination with EGFR inhibitors.
Target Audience
The primary target audience includes pharmaceutical companies focused on oncology drug development and clinical researchers investigating novel cancer therapies.
Features
- OMO-1: Oral, highly selective small molecule MET kinase inhibitor
- OMO-1: Demonstrated single agent and combination activity in preclinical cancer models
- OMO-2: Dual MET and RAS pathway inhibitor
- OMO-2: Investigated as a targeted therapy for lung cancer
- OMO-2: Potential for broader oncology applications in combination with EGFR inhibitors